Portal Biotech Raises $35 Million Series A, Leveraging AI to Deliver the World’s First Full-Length Single-Molecule Protein Sequencer
Notified -
Globe Newswire30-06-2025, 22:28
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00